EU-301 (MVR CAR-T)

N/A

Report date: 2025/01/26 19:26:47

Base Information

Drug NameEU-301 (MVR CAR-T)
Drug Alias NameAnti-MVR/HLA-DR CAR-T Cell Therapy (Eutilex)CAR T-cell therapy (Eutilex)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionHistocompatibility antigens class II inhibitors
TargetsHistocompatibility antigens class II
Therapy Area/IndicationsColonic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEutilex
China Registration ClassN/A

Develop Information

Active CompaniesEutilex
Inactive CompaniesN/A
Active IndicationsColonic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A